Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Collegium Pharmaceutical, Inc. before investing.

In this article, we go over a few key elements for understanding Collegium Pharmaceutical, Inc.’s stock price such as:

• Collegium Pharmaceutical, Inc.’s current stock price and volume
• Why Collegium Pharmaceutical, Inc.’s stock price changed recently
• Upgrades and downgrades for COLL from analysts
• COLL’s stock price momentum as measured by its relative strength

About Collegium Pharmaceutical, Inc. (COLL)

Before we jump into Collegium Pharmaceutical, Inc.’s stock price, history, target price and what caused it to recently , let’s take a look at some background.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Want to learn more about Collegium Pharmaceutical, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Collegium Pharmaceutical, Inc..

Collegium Pharmaceutical, Inc.’s Stock Price as of Market Close

As of December 02, 2025, 4:00 PM, CST, Collegium Pharmaceutical, Inc.’s stock price was $47.510.

Collegium Pharmaceutical, Inc. is 0% from its previous closing price of $47.510.

During the last market session, Collegium Pharmaceutical, Inc.’s stock traded between $45.820 and $47.700. Currently, there are approximately 31.57 million shares outstanding for Collegium Pharmaceutical, Inc..

Collegium Pharmaceutical, Inc.’s price-earnings (P/E) ratio is currently at 28.8, which is high compared to the Pharmaceuticals industry median of 21.4. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Collegium Pharmaceutical, Inc. Stock Price History

Collegium Pharmaceutical, Inc.’s (COLL) price is currently up 1.78% so far this month.

During the month of December, Collegium Pharmaceutical, Inc.’s stock price has reached a high of $47.700 and a low of $45.820.

Over the last year, Collegium Pharmaceutical, Inc. has hit prices as high as $48.180 and as low as $23.230. Year to date, Collegium Pharmaceutical, Inc.’s stock is up 65.83%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Collegium Pharmaceutical, Inc. Stock’s Price to ?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 02, 2025, there were 0 analysts who downgraded Collegium Pharmaceutical, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Collegium Pharmaceutical, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Collegium Pharmaceutical, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Collegium Pharmaceutical, Inc.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Collegium Pharmaceutical, Inc. (COLL) by visiting AAII Stock Evaluator.

Relative Price Strength of Collegium Pharmaceutical, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 02, 2025, Collegium Pharmaceutical, Inc. has a weighted four-quarter relative price strength of 9.02%, which translates to a Momentum Score of 82 and is considered to be Very Strong.

Want to learn more about how Collegium Pharmaceutical, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Collegium Pharmaceutical, Inc. Stock Price: Bottom Line

As of December 2, 2025, Collegium Pharmaceutical, Inc.’s stock price is $47.510, which is 0% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Collegium Pharmaceutical, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.